WO2018137679A1 - Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile - Google Patents

Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile Download PDF

Info

Publication number
WO2018137679A1
WO2018137679A1 PCT/CN2018/074097 CN2018074097W WO2018137679A1 WO 2018137679 A1 WO2018137679 A1 WO 2018137679A1 CN 2018074097 W CN2018074097 W CN 2018074097W WO 2018137679 A1 WO2018137679 A1 WO 2018137679A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
water
dcm
dioxane
coupling reagent
Prior art date
Application number
PCT/CN2018/074097
Other languages
French (fr)
Inventor
Dawei Zhang
Original Assignee
Teligene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teligene Ltd filed Critical Teligene Ltd
Publication of WO2018137679A1 publication Critical patent/WO2018137679A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile, to processes for its preparation.
  • the invention provides a process for the preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile (Compound 7 in Formula (I) ) , which is characterized by using Compound 5 with Boc protecting group as Scheme 1:
  • the invention provides the key intermediates for the preparing Compound 7:
  • the invention provides a process for the preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile (Compound 7 in Formula (I) ) , which is characterized by using Compound 5 with Boc protecting group shown in Scheme 1:
  • the invention provided a process of preparing Compound 7, the ester group of Compound 1 is hydrolyzed with NaOH in THF/Water or MeOH/Water or acetone/Water or acetonitrile/water or isopropanol/Water or EtOH/Water into Compound 2 in the Step (1) , and more preferably, in THF/Water or MeOH/Water.
  • the invention provided a process of preparing Compound 7, the amide formation of Compound 2 and 3 optionally with a coupling reagent and in a non-reactive solvent, afforded Compound 4 in the Step (2) ;
  • the coupling reagent is selected from HATU, EDC, DCC, BOP, T 3 P, or HOBt, and with DIEA or DIPEA;
  • the non-reactive solvent is selected from DCM, DMF, or dioxane;
  • the coupling reagent is HATU, EDC, or DCC, and with DIEA or DIPEA;
  • the non-reactive solvent is selected from DCM, DMF, or dioxane.
  • the invention provided a process of preparing Compound 7, Compoud 4 is reacted with Boc-Glycine optionally in the present of a coupling reagent and in a non-reactive solvent to afford Compound 5 in the Step (3) ; more preferably, the coupling reagent is selected from HATU, EDC, DCC, BOP, T 3 P, or HOBt, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane; most preferably, the coupling reagent is HATU, EDC, or DCC, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane.
  • the coupling reagent is selected from HATU, EDC, or DCC, and with DIEA or DIPEA
  • the non-reactive solvent is selected from DCM, DMF, or dioxane.
  • the invention provided a process of preparing Compound 7, Compound 5 is intramolecularly cyclized into Compound 6 under palladium catalyzed condition in the Step (4) , more preferably, in the present of Pd (OAc) 2 , cataxiuma and KOAc, and in t-AmOH.
  • the invention provided a process of preparing Compound 7, Compound 6 is deprotected under acidic condition such as HCl in MeOH or dioxane in the Step (5) .
  • the invention provided a process of preparing Compound 7 in the Scheme 3:
  • the invention provides the key intermediates for the preparing Compound 7:
  • DMF means N, N-dimethylformamide.
  • DCM dichloromethane
  • HATU means 1- [Bis (dimethylamino) methylene] -1H-1, 2, 3-triazolo [4, 5-b] pyridinium 3-oxid hexafluorophosphate
  • DIPEA or DIEA means diisopropyl ethylamine.
  • DCC means Dicyclohexylcarbodiimide.
  • EDC means N- (3-dimethylaminopropyl) -N′-ethylcarbodiimide hydrochloride.
  • THF means tetrahydrofuran
  • EA means ethyl acetate.
  • HOBt means hydroxybenzotriazole
  • m-CPBA meta-Chloroperoxybenzoic acid.
  • Boc-Gly-OH means N- (tert-Butoxycarbonyl) glycine.
  • BOP means (Benzotriazol-1-yloxy) tris (dimethylamino) phosphonium hexafluorophosphate.
  • Pd (dppf) Cl 2 means [1, 1′-Bis (diphenylphosphino) ferrocene] dichloropalladium.
  • T 3 P means n-propylphosphonoic anhydride
  • Et 3 N means triethyl amine
  • Fmoc Fluorenylmethyloxycarbonyl
  • cataXium A means Di (1-adamantyl) -n-butylphosphine
  • Pd (OAc) 2 means palladium acetate

Abstract

The present application disclosed a process for the preparing (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile, characterized by using Compound 5 with Boc protecting group, which is more suitable for industrial production.

Description

Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile
CROSS REFERENCE
This invention claims the benefit of U.S. Provisional Patent Application No. 62/499,395, filed on January 25, 2017, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
The present invention relates to (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile, to processes for its preparation.
BACKGROUND OF THE INVENTION
Compound (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile is mentioned in WO2016/026423 and corresponds to the compound of the Formula (I) :
Figure PCTCN2018074097-appb-000001
The synthetic procedure described in WO2016/026423, although suitable, regarded as disadvantageous for commercial production. There is a need for improved manufacturing methods of compound described in Formula (I) . In  particular, there is a need to provide processes that fulfill one or more of the following criteria: scalable, safer, simpler, higher yielding and more economical when compared to known.
SUMMARY OF THE INVENTION
In the first aspect, the invention provides a process for the preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile (Compound 7 in Formula (I) ) , which is characterized by using Compound 5 with Boc protecting group as Scheme 1:
Figure PCTCN2018074097-appb-000002
In the second aspect, the invention provides the key intermediates for the preparing Compound 7:
Figure PCTCN2018074097-appb-000003
Figure PCTCN2018074097-appb-000004
DETAILED DESCRIPTION OF THE INVENTION
The initial designed synthesis of compound 7 in Formula (I) was described in Scheme 2. The protection of compound 1 with Boc-Glycine afforded compound A. The hydrolysis of compound A did not give the desire compound B, but generated compound C as the major product along with some compound 1. The protection of compound A with Fmoc-Glycine also afforded very low yield of desired product. Most of the Fmoc group was cleaved under various reaction conditions.
Scheme 2:
Figure PCTCN2018074097-appb-000005
In one embodiment, the invention provides a process for the preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile (Compound 7 in Formula (I) ) , which is characterized by using Compound 5 with Boc protecting group shown in Scheme 1:
Scheme 1
Figure PCTCN2018074097-appb-000006
in which includes the following steps:
(1) the ester group of Compound 1 is hydrolyzed into Compound 2;
(2) Compound 2 is coupled with Compound 3 to afford Compound 4;
(3) Compoud 4 is reacted with Boc-Glycine to generate Compound 5;
(4) Compound 5 is intramolecularly cyclized into Compound 6;
(5) Compound 6 is deprotected to afford Compound 7.
In one preferred embodiment, the invention provided a process of preparing Compound 7, the ester group of Compound 1 is hydrolyzed with NaOH in THF/Water or MeOH/Water or acetone/Water or acetonitrile/water or isopropanol/Water or EtOH/Water into Compound 2 in the Step (1) , and more preferably, in THF/Water or MeOH/Water.
In one preferred embodiment, the invention provided a process of preparing Compound 7, the amide formation of Compound 2 and 3 optionally with a coupling reagent and in a non-reactive solvent, afforded Compound 4 in the Step (2) ; more preferably, the coupling reagent is selected from HATU, EDC, DCC, BOP, T 3P, or HOBt, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane; most preferably, the coupling reagent is HATU,  EDC, or DCC, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane.
In one preferred embodiment, the invention provided a process of preparing Compound 7, Compoud 4 is reacted with Boc-Glycine optionally in the present of a coupling reagent and in a non-reactive solvent to afford Compound 5 in the Step (3) ; more preferably, the coupling reagent is selected from HATU, EDC, DCC, BOP, T 3P, or HOBt, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane; most preferably, the coupling reagent is HATU, EDC, or DCC, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane.
In one preferred embodiment, the invention provided a process of preparing Compound 7, Compound 5 is intramolecularly cyclized into Compound 6 under palladium catalyzed condition in the Step (4) , more preferably, in the present of Pd (OAc)  2, cataxiuma and KOAc, and in t-AmOH.
In one preferred embodiment, the invention provided a process of preparing Compound 7, Compound 6 is deprotected under acidic condition such as HCl in MeOH or dioxane in the Step (5) .
In specific embodiment, the invention provided a process of preparing Compound 7 in the Scheme 3:
Figure PCTCN2018074097-appb-000007
The ester group of Compound 1 was hydrolyzed with NaOH in THF/Water or MeOH/Water to give Compound 2. The amide formation of Compound 2 and 3 with HATU in DCM afforded Compound 4, which reacted with Boc-Glycine to generate Compound 5. The intramolecular cyclization of Compound 5 under palladium catalyzed condition afforded Compound 6. Deprotection of Boc group of Compound 6 led to the synthesis of Compound 7.
In anther embodiment, the invention provides the key intermediates for the preparing Compound 7:
Figure PCTCN2018074097-appb-000008
Figure PCTCN2018074097-appb-000009
Abbreviations
DMF means N, N-dimethylformamide.
DCM means dichloromethane.
HATU means 1- [Bis (dimethylamino) methylene] -1H-1, 2, 3-triazolo [4, 5-b] pyridinium 3-oxid hexafluorophosphate
DIPEA or DIEA means diisopropyl ethylamine.
DCC means Dicyclohexylcarbodiimide.
EDC means N- (3-dimethylaminopropyl) -N′-ethylcarbodiimide hydrochloride.
THF means tetrahydrofuran.
EA means ethyl acetate.
HOBt means hydroxybenzotriazole.
m-CPBA means meta-Chloroperoxybenzoic acid.
Boc-Gly-OH means N- (tert-Butoxycarbonyl) glycine.
BOP means (Benzotriazol-1-yloxy) tris (dimethylamino) phosphonium hexafluorophosphate.
Pd (dppf) Cl 2 means [1, 1′-Bis (diphenylphosphino) ferrocene] dichloropalladium.
T 3P means n-propylphosphonoic anhydride
Et 3N means triethyl amine
Fmoc means Fluorenylmethyloxycarbonyl
cataXium A means Di (1-adamantyl) -n-butylphosphine
Pd (OAc)  2 means palladium acetate
Example 1 (Compound 2)
Figure PCTCN2018074097-appb-000010
To a solution of Compound 1 (500 mg) in methanol and water was added 5 equivalents of NaOH and the reaction was stirred at room temperature overnight. The reaction solution was heated to 45℃ for another 4 hours and cooled down to room temperature. The reaction then was worked out to give Compound 2 (400 mg) . MS m/z 355 [M+1] .
Example 2 Synthesis of (R) -2- (1- ( (2-amino-5-bromopyridin-3-yl) oxy) ethyl) -4-fluorobenzoic acid (Compound 2)
Figure PCTCN2018074097-appb-000011
To a solution of compound 1 (10 g, 27 mmol) in MeOH (150 mL) were added a solution of NaOH (5.42 g, 13.55 mmol) in water (40 mL) . The mixture was heated at 40 ℃ for 10 h. Then cooled and evaporated under reduced pressure. The residue was added water (150 mL) and extracted with EA (50 mL) . The aqueous phase was adjusted to pH about 7 and extracted with EA (50 mL*3) . The combined organic phase was washed with brine, dried with Na 2SO 4 and  evaporated under reduced pressure to provide compound 2 (9.5 g, 98.7%yield) as a light yellow solid.  1H-NMR (CD 3OD, 300 MHz) : δ 8.07-8.12 (m, 1H) , 7.50 (s, 1H) , 7.38-7.34 (m, 1H) , 7.15-7.09 (m, 1H) , 6.88 (s, 1H) , 6.49 (t, J=6.0 Hz, 1H) , 1.66 (dd, J=6.3 Hz, 3H) . MS m/z 355 [M+1] .
Example 2 (Compound 4)
Figure PCTCN2018074097-appb-000012
To a solution of Compound 2 (100 mg) in DCM was added Compound 3, HATU, and DIEPA, the reaction was stirred overnight and workout to give desired product Compound 4 (100 mg) . MS m/z 487 [M+1] .
Example 3 Synthesis of (R) -2- (1- ( (2-amino-5-bromopyridin-3-yl) oxy) ethyl) -N- ( (5-cyano-1-methyl-1H-pyrazol-3-yl) methyl) -4-fluoro-N-methylbenzamide (Compound 4)
Figure PCTCN2018074097-appb-000013
To a solution of compound 3 (8.4 g, 45.07 mmol) , HATU (17.12 g, 45.07 mmol) and DIEA (14.53 g, 112.68 mmol) in DMF (200 mL) was added compound 2 (10.0 g, 28.17 mmol) under N 2 with ice-water bath. The mixture was stirred overnight at room temperature. Water (500 mL) was was added and extracted with EA (100 mL*3) . The combined organic phase was washed with brine, dried with Na 2SO 4 and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE: EA =2: 1 to 1: 1, v: v) to provide compound 4 (10.0 g, 73%yield) as an off-white solid.  1H-NMR (DMSO, 300 MHz) : δ= 7.35-7.54 (m, 3H) , 6.99-7.23 (m, 3H) , 6.09-6.29 (m, 2H) , 5.48-5.52 (m, 1H) , 4.66-4.75 (m, 1H) , 4.45-4.66 (m, 1H) , 3.92-3.95 (m, 3H) , 2.97 (s, 1H) , 2.76 (s, 1H) . MS: 488 [M+1]  +. MS m/z 487 [M+1] .
Example 4 (Compound 5)
Figure PCTCN2018074097-appb-000014
To a solution of Compound 4 in dioxane were added Boc-Glycine, HATU and DIEA. The reaction was heated at 80℃ and followed by TLC until the completion. Worked out to give the desire product Compound 5. MS m/z 644 [M+1] .
Example 5 Synthesis of (R) -tert-butyl (2- ( (5-bromo-3- (1- (2- ( ( (5-cyano-1-methyl-1H-pyrazol-3-yl) methyl) (methyl) carbamoyl) -5-fluorophenyl) ethoxy) pyridin-2-yl) amino) -2-oxoethyl) carbamate (Compound 5)
Figure PCTCN2018074097-appb-000015
A solution of compound 4 (10.5 g, 21.56 mmol) , Boc-Gly-OH (13.2 g, 75.46 mmol) , HATU (32.77 g, 96.24 mmol) and DIEA (16.68 g, 129 mmol) in dioxane (300 ml) was heated to 80 ℃ for 8 h under N 2. The solvent was removed under reduced pressure. Water (150 mL) was added and extracted with EA (100 ml*3) , the combined organic phase was washed with brine, dried with Na 2SO 4 and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE: EA =2: 1, v: v) to provide compound 5 (9.0 g, 64.7%yield) as a yellow solid.  1H-NMR (DMSO, 400 MHz) : δ= 9.87-9.88 (d, J=1.6 Hz, 1H) , 7.65-7.69 (m, 1H) ,  7.42-7.46 (m, 1H) , 7.14-7.25 (m, 1H) , 5.56-5.57 (m, 1H) , 4.36-4.75 (m, 2H) , 3.96-4.046 (m, 3H) , 3.96-4.06 (m, 2H) , 3.01 (s, 1H) , 2.84 (s, 2H) , 1.55 (d, J=4.4 Hz, 3H) , 1.40 (s, 1H) . MS m/z 644 [M+1] .
Example 6 (Compound 6)
Figure PCTCN2018074097-appb-000016
To a solution of Compound 5 in t-AmOH were added Pd (OAc)  2, catax1 and KOAc. The reaction was heated to reflux for overnight to give desired product Compound 6. MS m/z 564 [M+1] .
Example 7 Synthesis of compound (6)
Figure PCTCN2018074097-appb-000017
To a solution of compound 5 (7.0g, 10.87 mmol) in t-AmOH (200 mL) was added Pd(OAc) 2 (650 mg, 2.90 mmol) , cataxiuma (2.08 g, 5.80 mmol) and KOAc (5.35 g, 54.35 mmol) . The mixture was heated at 120 ℃ overnight under N 2. After cooled and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (DCM: MeOH =100: 1, v: v) to provide the yellow solid, then the solid was again purified by silica gel column chromatography (EA) to provide compound 6 (1.5g, 24.5%yield) as a yellow solid.  1H-NMR (CD3OD, 400 MHz) : δ= 7.96 (s, 1H) , 7.54-7.57 (m, 1H) , 7.40-7.43  (m, 1H) , 7.21 (s, 1H) , 7.10-7.13 (m, 1H) , 5.77 (t , J=6.0 Hz, 1H) , 4.39-4.51 (m, 2H) , 4.07-4.12 (m, 5H) , 3.12 (s, 3H) , 1.81 (dd , J=6.0 Hz, 3H) , 1.50 (s, 9H) . MS m/z 564 [M+1] .
Example 8 (Compound 7)
Figure PCTCN2018074097-appb-000018
To compound 6 in DCM was added HCl (4N in dioxane, 2ml) at 0℃, the mixture was stirred at 0℃ for another 6 hr, stop the reaction and evaporated to be dry, to the residue was added water (10ml) , the mixture was extracted with DCM (2ml x2) , the DCM layer was discarded, the water layer was adjusted pH to 8-9 by NaOH (1N) and then filtered, the solid was washed by water (2ml) and dried to give the crude product, the crude product was purified by silica gel column chromatography (DCM: MeOH /30: 1 to 15: 1) to give the desired product as an off-white solid. MS m/z 464 [M+1] .
Example 9 (Compound 7)
Figure PCTCN2018074097-appb-000019
A solution of compound 6 (2.2 g, 3.91 mmol) in DCM (10 mL) was added TFA (2 ml) , then the solution was stirred for 2 h at room temperature. The solution was evaporated under reduced pressure. Water (20 mL) was added and extracted with DCM (20 ml) , the aqueous phase was adjusted to pH about 8～9 and extracted with DCM (20*5) . The combined organic phase was  dried over anhydrous Na 2SO 4. The solvent was evaporated under reduced pressure and the residue was purified by pre-HPLC to provide Compound 7 (340 mg, 18.9%yield) as a white solid.  1H-NMR (CD3OD, 400 MHz) : δ= 8.03 (d , J=1.6 Hz, 1H) , 7.52-7.55 (m, 1H) , 7.41-7.44 (m, 1H) , 7.23 (d , J=1.2 Hz, 1H) , 7.10-7.14 (m, 1H) , 5.78 (t , J=5.6 Hz, 1H) , 4.40-4.52 (m, 2H) , 4.10 (s, 3H) , 3.63 (s, 2H) , 3.13 (s, 3H) 1.80 (dd , J=6.0 Hz, 3H) . MS m/z 464 [M+1] .

Claims (8)

  1. A process for preparing of Compound 7, in which includes the following steps:
    (1) the ester group of Compound 1 is hydrolyzed into Compound 2;
    (2) Compound 2 is coupled with Compound 3 to afford Compound 4;
    (3) Compoud 4 is reacted with Boc-Glycine to generate Compound 5;
    (4) Compound 5 is intramolecularly cyclized into Compound 6;
    (5) Compound 6 is deprotected to afford Compound 7:
    Figure PCTCN2018074097-appb-100001
  2. The process of Claim1, wherein Compound 1 is hydrolyzed with NaOH in THF/Water or MeOH/Water or acetone/Water or acetonitrile/water or isopropanol/Water or EtOH/Water into Compound 2 in the Step (1) , and more preferably, in THF/Water or MeOH/Water.
  3. The process of Claim1, wherein the amide formation of Compound 2 and 3 optionally with a coupling reagent and in a non-reactive solvent, afforded Compound 4 in the Step (2) ; more preferably, the coupling reagent is selected from HATU, EDC, DCC, BOP, T 3P, or HOBt, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane; most preferably, the coupling reagent is HATU, EDC, or DCC, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane.
  4. The process of Claim1, wherein Compoud 4 is reacted with Boc-Glycine optionally in the present of a coupling reagent and in a non-reactive solvent to afford Compound 5 in the Step (3) ; more preferably, the coupling reagent is selected from HATU, EDC, DCC, BOP, T 3P, or HOBt, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane; most preferably, the coupling reagent is HATU, EDC, or DCC, and with DIEA or DIPEA; the non-reactive solvent is selected from DCM, DMF, or dioxane.
  5. The process of Claim1, wherein Compound 5 is intramolecularly cyclized into Compound 6 under palladium catalyzed condition in the Step (4) , more preferably, in the present of Pd (OAc) 2, cataxiuma and KOAc, and in t-AmOH.
  6. The process of Claim1, wherein Compound 6 is deprotected under acidic condition such as HCl in MeOH or dioxane in the Step (5) .
  7. Compound 5 as a key intermediate for the process of Claim 1
    Figure PCTCN2018074097-appb-100002
  8. Compound 6 as a key intermediate for the process of Claim 1
    Figure PCTCN2018074097-appb-100003
PCT/CN2018/074097 2017-01-25 2018-01-25 Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile WO2018137679A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762499395P 2017-01-25 2017-01-25
US62/499,395 2017-01-25

Publications (1)

Publication Number Publication Date
WO2018137679A1 true WO2018137679A1 (en) 2018-08-02

Family

ID=62978105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/074097 WO2018137679A1 (en) 2017-01-25 2018-01-25 Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile

Country Status (1)

Country Link
WO (1) WO2018137679A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109651398A (en) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 A method of synthesis Laura replaces the bromo-derivative intermediate of Buddhist nun and catalyzes and synthesizes Laura for Buddhist nun
WO2020108522A1 (en) * 2018-11-28 2020-06-04 深圳市塔吉瑞生物医药有限公司 Preparation method for deuterated macrocyclic compound
CN111362967A (en) * 2020-04-28 2020-07-03 南京雷正医药科技有限公司 Benzoxadiazatetetradecene derivatives and use thereof
WO2020228747A1 (en) 2019-05-14 2020-11-19 Teligene Ltd Substituted macrocycles useful as kinase inhibitors
CN112321604A (en) * 2019-08-05 2021-02-05 华东理工大学 Macrocyclic JAK2 inhibitor and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101654473A (en) * 2009-08-13 2010-02-24 上海力智生化科技有限公司 Synthesis method of amino-protecting glycine dipeptidase derivant
US20140135339A1 (en) * 2012-03-06 2014-05-15 Pfizer Inc. Macrocyclic derivatives for the treatment of diseases
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
CN106146614A (en) * 2015-05-14 2016-11-23 沈阳科海医药科技有限公司 A kind of preparation method of RGD tripeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101654473A (en) * 2009-08-13 2010-02-24 上海力智生化科技有限公司 Synthesis method of amino-protecting glycine dipeptidase derivant
US20140135339A1 (en) * 2012-03-06 2014-05-15 Pfizer Inc. Macrocyclic derivatives for the treatment of diseases
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
CN106146614A (en) * 2015-05-14 2016-11-23 沈阳科海医药科技有限公司 A kind of preparation method of RGD tripeptides

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020108522A1 (en) * 2018-11-28 2020-06-04 深圳市塔吉瑞生物医药有限公司 Preparation method for deuterated macrocyclic compound
CN111233833A (en) * 2018-11-28 2020-06-05 深圳市塔吉瑞生物医药有限公司 Preparation method of deuterated macrocyclic compound
JP2022513151A (en) * 2018-11-28 2022-02-07 深▲チェン▼市塔吉瑞生物医薬有限公司 Method for preparing deuterated macrocycle
JP7347852B2 (en) 2018-11-28 2023-09-20 深▲チェン▼市塔吉瑞生物医薬有限公司 Method for preparing deuterated macrocycles
CN109651398A (en) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 A method of synthesis Laura replaces the bromo-derivative intermediate of Buddhist nun and catalyzes and synthesizes Laura for Buddhist nun
WO2020228747A1 (en) 2019-05-14 2020-11-19 Teligene Ltd Substituted macrocycles useful as kinase inhibitors
EP3844166A4 (en) * 2019-05-14 2021-12-15 Teligene Ltd. Substituted macrocycles useful as kinase inhibitors
JP2022504578A (en) * 2019-05-14 2022-01-13 テリジーン リミテッド Substituted macrocycles useful as kinase inhibitors
JP7345901B2 (en) 2019-05-14 2023-09-19 テリジーン リミテッド Substituted macrocycles useful as kinase inhibitors
CN112321604A (en) * 2019-08-05 2021-02-05 华东理工大学 Macrocyclic JAK2 inhibitor and application thereof
CN111362967A (en) * 2020-04-28 2020-07-03 南京雷正医药科技有限公司 Benzoxadiazatetetradecene derivatives and use thereof
CN111362967B (en) * 2020-04-28 2021-09-07 南京雷正医药科技有限公司 Benzoxadiazatetetradecene derivatives and use thereof

Similar Documents

Publication Publication Date Title
WO2018137679A1 (en) Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile
KR101467598B1 (en) Process for hcv protease inhibitor intermediate
EP3152191B1 (en) Improved process for making duocarmycin prodrugs
WO2014016740A2 (en) Improved process for the preparation of pralatrexate
CA3030555A1 (en) Intermediates in processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides_____________
CA2810393C (en) Method of preparing 3-amino-4-(2-oxo-piperidin-1-yl)-butyric acid derivative for synthesizing medicament
WO2018210336A1 (en) Glyx-13 preparation method and intermediate component thereof
KR20160138538A (en) A process for preparation of sodium (2s, 5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate
KR100847331B1 (en) Method of preparing docetaxel and intermediates used therein
US9573971B2 (en) Method of preparation of antiviral compounds and useful intermediates thereof
US10870650B2 (en) Process for the preparation of amorphous idelalisib
KR20180118054A (en) Production Method of Intermediate Compound for Synthesizing Medicament
WO2017109524A1 (en) Method and intermediate for the production of baricitinib
WO2017130221A1 (en) Improved process for the preparation of idelalisib
CA2819381A1 (en) Method of making azaindazole derivatives
CA3021507A1 (en) Processes for the preparation of veliparib and intermediates thereof
JP7279134B2 (en) Method for producing prolinamide compound
CN117659032A (en) Intermediate of ecteinascidin derivative and synthetic method thereof
CN115385926A (en) Preparation method of connection base drug conjugate and intermediate thereof
CN115215921A (en) Preparation method of connection base drug conjugate and intermediate thereof
CN116897149A (en) Preparation method of linker drug conjugate and intermediate thereof
CN111655670A (en) Process for preparing 2-chloro-4-nitroimidazole derivatives
PL237600B1 (en) Tetrazole derivatives of cinchona tree alkaloids and method for producing them
KR101691353B1 (en) Manufacturing method for Bortezomib and new intermediate thereof
CN110577551A (en) Camptothecin-glycine-5, 6-dibromo norcantharidin conjugate and application thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18745433

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18745433

Country of ref document: EP

Kind code of ref document: A1